Oncology: International Journal of Cancer Research and Treatment
Fecha de publicación: 25 september 2018
Autores: Mutai R., Goldvaser H., Shochat T., Peretz I., Sulkes A.,Yerushalmi R.
Background: Lymphovascular invasion (LVI) is considered a negative prognostic factor in early breast cancer, but its role in decision-making regarding adjuvant chemotherapy is unclear in the current era of molecular profiling. This study sought to evaluate the association of LVI status with the recurrence score (RS) on the multigene Oncotype DX (ODX) assay and its impact on outcome.